<DOC>
	<DOCNO>NCT00859508</DOCNO>
	<brief_summary>Primary Objective : To demonstrate SyntheCelTM Dura Replacement perform similarly substantially equivalent dura replacement repair cranial dura patient undergoing surgical repair cranial dura .</brief_summary>
	<brief_title>Study SyntheCelTM Dura Replacement Other Dura Replacements</brief_title>
	<detailed_description />
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Patient 18 75 year age Patient schedule elective cranial procedure require dural incision Patient MRI earlier two month prior date enrollment Surgical wound expect Class I/clean Patient available willing participate investigation duration study Patient sign write Informed Consent participate study prior study mandate determination procedure . This include MRIs may perform prior obtain informed consent . Patient cranial metallic implant ( ) would interfere evaluation device recovery Patient somnolent comatose ( Glasgow score &lt; 8 ) Patient prior intracranial neurosurgical procedure anatomical location Patient require use dural adhesive sealant Patient know hydrocephalus Patient 's life expectancy le 6 month Patient systemic infection ( e.g . urinary tract infection ( UTI ) , active pneumonia ) evidence surgical site infection , fever &gt; 101°F , positive blood culture and/or positive chest xray acute infectious process Patient know allergy device component ( cellulose ) Patient acute cranial trauma surgical case Patient local cranial infection Patient chemotherapy and/or radiation treatment within 12 week prior surgery , chemotherapy and/or radiation treatment plan 10 week post surgery Patient clinically diagnose malignancy ( basal cell carcinoma low grade glioma ) , uncontrolled diabetes , sepsis , systemic collagen disease Patient creatinine level &gt; 2.0 mg/dL Patient total bilirubin level &gt; 2.5 mg/dL Patent clinically significant coagulopathy partial thromboplastin time ( PTT ) ≥ 35 , international normalize ratio ( INR ) ≥ 1.2 , receive Warfarin Coumadin Patient compromise immune system autoimmune disease ( white blood cell ( WBC ) count &lt; 4000/uL &gt; 20,000/uL ) Patient participate another clinical trial use investigational devices/drugs Patient pregnant breastfeeding wish become pregnant course study Patient unable unwilling sign consent form</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>dura repair follow cranial surgery</keyword>
</DOC>